ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2024年9月26日

查看全文
  • Daniel Fernández-Llaneza,
  • Romy M. P. Vos,
  • Joris E. Lieverse,
  • Helen R. Gosselt,
  • Sandra L. Kane-Gill,
  • Teun van Gelder,
  • Joanna E. Klopotowska,
  • Ameen Abu-Hanna,
  • Annemiek Dorgelo,
  • Annette ten Teije,
  • Birgit A. Damoiseaux,
  • Cornelis Boersma,
  • Dave A. Dongelmans,
  • David H. de Koning,
  • Erol S. Hofmans,
  • Evelien Tiggelaar,
  • Frank van Harmelen,
  • Giovanni Cinà,
  • Gerty Holla,
  • Hilda J. de Jong,
  • Iacopo Vagliano,
  • Jan Pander,
  • Jasper M. Boomker,
  • Jurjen van der Schans,
  • Kitty J. Jager,
  • Linda Dusseljee-Peute,
  • Luuk B. Hilbrands,
  • Marianne le Comte,
  • Marieke A. R. Bak,
  • Mariette van den Hoven,
  • Martijn G. Kersloot,
  • Menno Maris,
  • Nicolette F. de Keizer,
  • Otto R. Maarsingh,
  • Paul Blank,
  • Piet Heingraaf,
  • Ron Herings,
  • Ron J. Keizer,
  • Ronald Cornet,
  • Ruben Boyd,
  • Sebastiaan L. Knijnenburg,
  • Sipke Visser,
  • Stephanie Medlock,
  • Tjerk S. Heijmens Visser,
  • Vianda S. Stel,
  • Wanda Konijn

摘要

Introduction and Objective

The recent rise in acute kidney injury (AKI) incidence, with approximately 30% attributed to potentially preventable adverse drug events (ADEs), poses challenges in evaluating drug-induced AKI due to polypharmacy and other risk factors. This study seeks to consolidate knowledge on the drugs with AKI potential from four distinct sources: (i) bio(medical) peer-reviewed journals; (ii) spontaneous reporting systems (SRS); (iii) drug information databases (DIDs); and (iv) NephroTox website. By harnessing the potential of these underutilised sources, our objective is to bridge gaps and enhance the understanding of drug-induced AKI.

Methods

By searching Medline, studies with lists of drugs with AKI potential established through consensus amongst medical experts were selected. A final list of 63 drugs was generated aggregating the original studies. For these 63 drugs, the AKI reporting odds ratios (RORs) using three SRS databases, the average frequency of ADEs from four different DIDs and the number of published studies identified via NephroTox was reported.

Results

Drugs belonging to the antivirals, antibacterials, and non-steroidal anti-inflammatory pharmacological classes exhibit substantial consensus on AKI potential, which was also reflected in strong ROR signals, frequent to very frequent AKI-related ADEs and a high number of published studies reporting adverse kidney events as identified via NephroTox. Renin-angiotensin aldosterone system inhibitors and diuretics also display comparable signal strengths, but this can be attributed to expected haemodynamic changes. More variability is noted for proton-pump inhibitors.

Conclusions

By integrating four disjointed sources of knowledge, we have created a novel, comprehensive resource on drugs with AKI potential, contributing to kidney safety improvement efforts.